163 related articles for article (PubMed ID: 22143851)
1. Usage and equity of access to isotretinoin in New Zealand by deprivation and ethnicity.
Moodie P; Jaine R; Arnold J; Bignall M; Metcalfe S; Arroll B
N Z Med J; 2011 Nov; 124(1346):34-43. PubMed ID: 22143851
[TBL] [Abstract][Full Text] [Related]
2. Terminations of pregnancy associated with isotretinoin use in New Zealand.
Moodie P; Jaine R; Arnold J; Metcalfe S; Bignall M; Arroll B
N Z Med J; 2011 Jul; 124(1339):59-66. PubMed ID: 21952331
[TBL] [Abstract][Full Text] [Related]
3. Isotretinoin (roaccutane) usage--a South African consensus guideline. National Dermatology Working Group.
S Afr Med J; 1997 Oct; 87(10 Pt 2):1410-3. PubMed ID: 11496385
[TBL] [Abstract][Full Text] [Related]
4. Ocular adverse effects of systemic treatment with isotretinoin.
Neudorfer M; Goldshtein I; Shamai-Lubovitz O; Chodick G; Dadon Y; Shalev V
Arch Dermatol; 2012 Jul; 148(7):803-8. PubMed ID: 22508771
[TBL] [Abstract][Full Text] [Related]
5. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential.
AlGhamdi KM; Khurram H; Asiri YA; Mandil A
Int J Dermatol; 2011 Sep; 50(9):1094-8. PubMed ID: 22126870
[TBL] [Abstract][Full Text] [Related]
6. Myths of isotretinoin therapy in patients with acne: a personal opinion.
Alcalay J
J Drugs Dermatol; 2004; 3(2):179-82. PubMed ID: 15098974
[TBL] [Abstract][Full Text] [Related]
7. Low-dose schema of isotretinoin in acne vulgaris.
Mandekou-Lefaki I; Delli F; Teknetzis A; Euthimiadou R; Karakatsanis G
Int J Clin Pharmacol Res; 2003; 23(2-3):41-6. PubMed ID: 15018017
[TBL] [Abstract][Full Text] [Related]
8. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne.
Gollnick HP; Graupe K; Zaumseil RP
Eur J Dermatol; 2001; 11(6):538-44. PubMed ID: 11701404
[TBL] [Abstract][Full Text] [Related]
9. Capitation funding of primary health organisations in New Zealand: are enrolled populations being funded according to need?
Langton J; Crampton P
N Z Med J; 2008 Apr; 121(1272):47-58. PubMed ID: 18425154
[TBL] [Abstract][Full Text] [Related]
10. Isotretinoin in Denmark -- 20 years on.
Wildfang IL; Nielsen NH; Jemec GB; Ibsen HH; Avnstorp C
J Dermatolog Treat; 2002 Sep; 13(3):151-2. PubMed ID: 12227880
[No Abstract] [Full Text] [Related]
11. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin.
Rademaker M
Australas J Dermatol; 2010 Nov; 51(4):248-53. PubMed ID: 21198520
[TBL] [Abstract][Full Text] [Related]
12. Medication and medical service utilization for acne 1995-1998.
Stern RS
J Am Acad Dermatol; 2000 Dec; 43(6):1042-8. PubMed ID: 11100021
[TBL] [Abstract][Full Text] [Related]
13. The role of isotretinoin in acne therapy: why not as first-line therapy? facts and controversies.
Rigopoulos D; Larios G; Katsambas AD
Clin Dermatol; 2010; 28(1):24-30. PubMed ID: 20082946
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in women with breast cancer: inequalities by ethnicity and socioeconomic position in New Zealand.
McKenzie F; Jeffreys M; 't Mannetje A; Pearce N
Cancer Causes Control; 2008 May; 19(4):403-11. PubMed ID: 18066672
[TBL] [Abstract][Full Text] [Related]
15. Psychological impact of isotretinoin treatment in patients with moderate and severe acne.
Simić D; Situm M; Letica E; Penavić JZ; Zivković MV; Tomić T
Coll Antropol; 2009 Dec; 33 Suppl 2():15-9. PubMed ID: 20120397
[TBL] [Abstract][Full Text] [Related]
16. [Acne flare-up and deterioration with oral isotretinoin].
Chivot M
Ann Dermatol Venereol; 2001 Mar; 128(3 Pt 1):224-8. PubMed ID: 11319385
[TBL] [Abstract][Full Text] [Related]
17. Reducing health disparities through primary care reform: the New Zealand experiment.
Hefford M; Crampton P; Foley J
Health Policy; 2005 Apr; 72(1):9-23. PubMed ID: 15760695
[TBL] [Abstract][Full Text] [Related]
18. Does mortality vary between pacific groups in New Zealand? Estimating Samoan, Cook Island Maori, Tongan, and Niuean mortality rates using hierarchical Bayesian modelling.
Blakely T; Richardson K; Young J; Callister P; Didham R
N Z Med J; 2009 Dec; 122(1307):18-29. PubMed ID: 20148041
[TBL] [Abstract][Full Text] [Related]
19. Does the teratogenicity of isotretinoin outweigh its benefits?
Jordan AY; Parks L; Chen SC; Higgins K; Fleischer AB; Feldman SR
J Dermatolog Treat; 2005; 16(4):190-2. PubMed ID: 16249139
[No Abstract] [Full Text] [Related]
20. Isotretinoin does not prolong QT intervals and QT dispersion in patients with severe acne: a surprising finding for a drug with numerous side effects.
Dursun R; Alpaslan M; Caliskan M; Ciftci O; Kulaksizoglu S; Seckin D; Muderrisoglu H
J Drugs Dermatol; 2011 Jul; 10(7):710-4. PubMed ID: 21720652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
